ALONG with helium, neon, argon, krypton, and radon, xenon is one of the noble gases, i.e. , it is an element whose outer shell is filled with electrons. Although the two lowest-molecular-weight noble gases, helium and neon, have very small electron shells and no anesthetic actions, the anesthetic properties of xenon have been recognized for almost 50 yr. 1With its filled outer electron shell, xenon exists as a monatomic gas under normothermic and normobaric conditions. Although it is virtually inert and does not form covalent bonds with other elements (except under extreme conditions), the very large electron shell of xenon can be polarized and distorted by nearby molecules (creating an induced dipole). This distortion of the electron orbitals permits xenon to interact with and bind to proteins such as myoglobin 2as well as to bilayer lipids, particularly in the region of the more polar headgroups. 3Its oil/gas partition coefficient of 1.9 is higher than the lighter noble gases. The ability of xenon to interact with cell proteins and cell membrane constituents is presumably responsible for its anesthetic potency. Xenon inhibits the plasma membrane Ca2+pump, 4an action similar to that of volatile anesthetics, which may be responsible for an increase in neuronal Ca2+concentrations and altered excitability. Xenon seems to inhibit the nociceptive responsiveness of spinal dorsal horn neurons, 5an effect that may be mediated by inhibition of N -methyl-D-aspartate receptors. 6

With a blood/gas partition coefficient of 0.115, xenon is the least soluble gas that may be used for anesthesia. 7During the past decade, it has received increasing study as an anesthetic agent with many attractive properties. Based on abstracts and reports in the literature, xenon has been shown to not alter voltage-gated ion channels in the myocardium, 8nor does it sensitize the myocardium to the dysrhythmogenic effects of epinephrine. 9Studies in patients 10and in cardiomyopathic dogs 11have demonstrated that xenon does not depress the myocardial contractility. Effects on the vasculature remain to be better defined, but xenon has no apparent effects on mesenteric vascular resistance. This apparent lack of effect in cardiovascular tissues may be responsible for its minimal effects on the cardiovascular system and may make xenon particularly useful in situations in which cardiovascular stability needs to be maintained. In addition to cardiovascular stability, a number of features makes xenon a nearly ideal anesthetic gas: rapid induction and emergence, a sufficient analgesic and hypnotic effect in a mixture with 30% oxygen, the absence of metabolism, undisturbed ventilation and pulmonary function, and lack of triggering of malignant hyperthermia. With a human minimum alveolar concentration value of 0.71 12(> twofold higher in some other species;table 1), the gas is optimally suited to be used as an inhalation anesthetic in a mixture with 30% oxygen. However, at concentrations > 60%, xenon increases the cerebral blood flow, 10and there can be retention of a considerable amounts of the gas in the bowels and fatty tissues. Up to this point, no data are available concerning the suitability of xenon in patients suffering from increased intracranial pressure or bowel obstruction. Nevertheless, the use of xenon as an anesthetic agent is promising and has been submitted for regulatory medical approval in Europe.

Table 1. Physical and Biologic Characteristics of Xenon

Compiled from references 7, 20–22.

Except for radon, xenon is the rarest noble gas, being present in atmospheric air in a concentration of no more than 0.086 ppm. Thus, the air of a normal living room with a volume of 50 m3contains only 4 ml xenon. The high molecular weight of xenon (131.2 d) gives it a density more than four times greater than air. Xenon is recovered in the process of air liquification, and after several separation processes, a purity of 99.995% can be obtained. The current world production of xenon is approximately six million liters per year. One million liters of xenon per year is already expended in medical uses, with half of this amount being used for anesthetic purposes. 13Xenon has been used for decades to study blood flow and gas distribution in the lung, although recent technical developments have expanded its use in magnetic resonance imaging. 14The yearly production is predicted to increase during the next 3 yr to 9.5 million liters. Currently, there is an increasing demand for this gas because of a recently launched project by the United States aerospace industry that uses xenon ion engines to maneuver satellites.

Corresponding to its rarity, xenon is expensive. During the last 2 yr, the price has increased from approximately $5 (U.S.) to approximately$10 per liter, and further changes are unpredictable. Because xenon is rare and expensive, the use of this gas as an anesthetic agent can be justified only if its waste is reduced to the absolute minimum. It must be applied via  rebreathing systems using the lowest possible gas flows. If 70% xenon is administered using a fresh gas flow as low as 0.5 l/min, during a 2-h anesthetic procedure, the efficiency would not even reach 20%, i.e. , less than 20% of the xenon delivered into the breathing system would actually be taken up by the patient, leaving > 80% (approximately 34 l) to be spilled out into the atmosphere as waste. Closed-system anesthesia is the only economically acceptable technique for application of xenon for anesthetic purposes. An electronically controlled anesthesia delivery system that continuously monitors gas concentrations inside the breathing circuit may be used for this purpose (xenon concentration can be determined by heat conductivity or by a characteristic radiofrequency response). A closed loop-feedback control mechanism delivers xenon and oxygen into the system in the amount needed to maintain constant gas concentrations and circulating gas volume. The usual manual control of a closed circuit may also be used. Because of its high density, the presence of xenon may degrade the accuracy of certain respiratory flowmeters. 15

For practical clinical use, nitrogen must first be washed out on induction of anesthesia by applying high-flow pure oxygen over a period of at least 5 min, typically accompanied by administration of a combination such as fentanyl (3 μg/kg), propofol (2 mg/kg), and a muscle relaxant. After endotracheal intubation, the patient is connected to the ventilator of an appropriate anesthetic delivery system. The hypnotic concentration of 40–45% xenon is established after 1.5 min, reaching the desired concentration of 60–70% in approximately 8 min. A small supplementary dose of fentanyl may be given just before skin incision.

If xenon is applied via  a closed rebreathing system after complete denitrogenation, 60–70% inspired xenon results in approximately 6 l being taken up in the first hour in an average adult, with 9–15 l being consumed in the first 2 h of xenon administration (fig. 1A). 16Some of the gas taken up may be lost to the atmosphere from the skin and surgically exposed tissues. Washout of the drug follows a similar time course (fig. 1B). Because xenon is substantially less soluble than nitrous oxide, its equilibration and washout causes less diffusion hypoxia. 17In addition, its low solubility permits a faster emergence than with nitrous oxide 18that is unaltered by the duration of the anesthetic. 19

Fig. 1. Uptake and elimination of xenon from patients undergoing surgical procedures. (A ) Uptake curves and mean uptake amounts (in liters) of xenon in seven patients (average weight = 72 ± 12 kg) after prior denitrogenation by breathing 100% oxygen for 15–20 min. (B ) Washout of xenon from patients no. 6 and 7 in (A ). (Reprinted from Luttropp et al.  16with permission.)

Fig. 1. Uptake and elimination of xenon from patients undergoing surgical procedures. (A ) Uptake curves and mean uptake amounts (in liters) of xenon in seven patients (average weight = 72 ± 12 kg) after prior denitrogenation by breathing 100% oxygen for 15–20 min. (B ) Washout of xenon from patients no. 6 and 7 in (A ). (Reprinted from Luttropp et al.  16with permission.)

If the total yearly production of approximately six million liters of xenon were available exclusively for anesthetic purposes, not more than 400,000 anesthetic procedures could be performed with this amount of gas. Recycling of the xenon contained in the gas escaping via  the exhaust port rather than wasting it into the atmosphere is the only way to guarantee the availability of a sufficient amount of xenon for routine use as an anesthetic gas in clinical practice. With currently available prototypes of recycling devices, approximately 70–90% of the xenon delivered into the system can be recovered, with a purity of approximately 90%. Oxygen and nitrogen make up the bulk of the impurities.

Because of its considerable expense and the fact that it cannot be synthesized, but rather must be extracted from the atmosphere, it is unlikely that xenon will gain widespread use. However, should delivery systems (closed circuit) become available with appropriate techniques for recycling the gas, xenon anesthesia may become more readily available. It may be a highly useful alternative in selected patients, e.g. , those with limited cardiovascular reserve. Over the next few years, it will be interesting to see better definition of its pharmacologic characteristics at the cellular level, as well as its effects and cost–benefit ratio in clinical trials.

## References

1.
Cullen SC, Gross EG: The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951; 113:580–2
2.
Trudell JR, Koblin DD, Eger IE II: A molecular description of how noble gases and nitrogen bind to a model site of anesthetic action. Anesth Analg 1998; 87:411–8
3.
Xu Y, Tang P: Amphiphilic sites for general anesthetic action? Evidence from 129Xe-[1H] intermolecular nuclear Overhauser effects. Biochim Biophys Acta 1997; 1323:154–62
4.
Franks JJ, Horn J-L, Janicki PK, Singh G: Halothane, isoflurane, xenon and nitrous oxide inhibit calcium ATPase pump activity in rat brain synaptic plasma membranes. A NESTHESIOLOGY 1995; 82:108–17
5.
Miyazaki Y, Adachi T, Utsumi J, Shichino T, Segawa H: Xenon has greater inhibitory effects on spinal dorsal horn neurons than nitrous oxide in spinal cord transected cats. Anesth Analg 1999; 88:893–7
6.
Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR: How does xenon produce anaesthesia (letter). Nature 1998; 396:324
7.
Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S: The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 1998; 80:255–6
8.
Rehmert GC, Kwok WM, Stadnicka A, Weigt HU, Georgieff M, Bosnjak ZJ: Xenon does not inhibit cardiac ion channels (abstract). A NESTHESIOLOGY 1998; 89:A595
9.
Kamibayashi T, Hayashi Y, Mammoto T, Mashimo T, Yamatodani A, Takada K, Kagawa K, Yoshiya I: Comparison of myocardial epinephrine sensitization during xenon, halothane, and nitrous oxide anesthesia in dogs (abstract). A NESTHESIOLOGY 1998; 89:A614
10.
Luttropp HH, Romner B, Perhag L, Eskilsson J, Fredriksen S, Werner O: Left ventricular performance and cerebral haemodynamics during xenon anaesthesia: A transesophageal echocardiography and transcranial Doppler sonography study. Anaesthesia 1993; 48:1045–9
11.
Hettrick DA, Pagel PS, Kersten JR, Tessmer JP, Bosnjak ZJ, Georgieff M, Warltier DC: Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. A NESTHESIOLOGY 1998; 89:1166–73
12.
Cullen SC, Eger EI II, Cullen BF, Gregory P: Observations on the anesthetic effect of the combination of xenon and halothane. A NESTHESIOLOGY 1969; 31:305–9
13.
Garrett ME: The production and availability of xenon (abstract). Presented at the annual meeting of the Association for Low Flow Anaesthesia, Ghent, Belgium, September 18–19, 1998
14.
Albert MS, Cates GD, Driehuys B, Happer W, Saam B, Springer CS Jr, Wishnia A: Biological magnetic resonance imaging using laser-polarized 129Xe. Nature 1994; 370:199–201
15.
Goto T, Saito H, Nakata Y, Uezono S, Ichinose F, Uchiyama M, Morita S: Effects of xenon on performance of various respiratory flowmeters. A NESTHESIOLOGY 1999; 90:555–63
16.
Luttropp HH, Thomasson S, Dahm S, Persson J, Werner O: Clinical experience with minimal xenon anaesthesia. Acta Anaesthesiol Scand 1994; 38:121–5
17.
Calzia E, Stahl W, Handschuh T, Marx T, Fröba G, Georgieff M, Radermacher P: Continuous arterial PO2and PCO2measurements during nitrous oxide and xenon elimination: Prevention of diffusion hypoxia. A NESTHESIOLOGY 1999; 90:829–34
18.
Lachmann B, Armbruster S, Schairer W, Landstra M, Trouwborst A, van Daal G-J, Kusuma A, Erdmann W: Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335:1413–5
19.
Goto T, Saito H, Nakata Y, Uezono S, Ichinose F, Morita S: Emergence times from xenon anaesthesia are independent of the duration of anaesthesia. Br J Anaesth 1997; 79:595–9
20.
Steward A, Allott PR, Cowles AL, Mapleson WW: Solubility coefficients for inhaled anaesthetics for water, oil, and biological media. Br J Anaesth 1973; 45:282–93
21.
Firestone LL, Miller JC, Miller KW: Appendix, tables of physical and pharmacological properties of anesthetics, Molecular and Cellular Mechanisms of Anesthetics. Edited by Roth SH, Miller KW. New York, Plenum Medical Book Co., 1986, pp 455–70
22.
Koblin DD, Zexu F, Eger EI II, Laster MJ, Gong D, Ionescu P, Halsey MJ, Trudell JR: Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexafluoride in rats: Helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg 1998; 87:419–24